Control of Disease Recurrence by Tumor-Infiltrating T Cells in Ovarian Cancer
Abstract
Ovarian cancer patients with large numbers of T cells in their tumor live longer after chemotherapy compared to patients with fewer T cells in their tumor. Our goal is to use modern genomic techniques to identify the antigens recognized by these T cells, with an emphasis on new antigens that arise during chemotherapy. To this end, we are collecting matched primary and recurrent tumor tissue from ovarian cancer patients (Tasks 1-2). This is progressing well, but the precise timeline is beyond our control as it depends (most unfortunately) on patients suffering a recurrence. In the meantime, we are also testing blood samples from patients for the emergence of new antibody responses during chemotherapy (Task 3). Tumor tissue from one patient to date is being subjected to whole transcriptome shotgun sequencing (Task 4). Finally, new methods are being developed to rapidly test the recognition of tumor mutations by T cells from patients (Task 5). Overall, this project is progressing on schedule and is already yielding publishable results.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 01, 2010
- Accession Number
- ADA549262
Entities
People
- Brad H Nelson
- John Webb
- Peter H. Watson
- Rob Holt
Organizations
- BC Cancer Agency